Russell Frank Company’s Clovis Oncology, Inc. CLVS Stock Holding History

Russell Frank Company’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,498	Closed	-$86K	–	3064
2015 Q4	$86K	Sell	2,498 -7,026	-74%	-$453K	﹤0.01%	2826
2015 Q3	$876K	Sell	9,524 -1,336	-12%	-$116K	﹤0.01%	2252
2015 Q2	$954K	Sell	10,860 -181,861	-94%	-$15.6M	﹤0.01%	2333
2015 Q1	$14.3M	Sell	192,721 -223,700	-54%	-$15.8M	0.03%	725
2014 Q4	$23M	Buy	416,421 +73,217	+21%	+$3.85M	0.04%	515
2014 Q3	$15.6M	Buy	343,204 +219,487	+177%	+$9.17M	0.03%	664
2014 Q2	$4.67M	Buy	123,717 +77,467	+167%	+$3.99M	0.01%	1355
2014 Q1	$2.42M	Buy	+46,250	New	+$3.4M	﹤0.01%	1671
2013 Q4	–	Sell	-682	Closed	-$41K	–	3139
2013 Q3	$41K	Sell	682 -11,422	-94%	-$810K	﹤0.01%	3146
2013 Q2	$811K	Buy	+12,104	New	+$544K	﹤0.01%	2147

Other funds holding CLVS

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Russell Frank Company's CLVS Position: Q1 2016 in Review

Russell Frank Company sold out of Clovis Oncology, Inc. (CLVS) in Q1 2016, closing a stake of 2,498 shares — an estimated $86K sold.

Russell Frank Company first reported a position in CLVS in Q2 2013 and held it in 10 quarters. The position peaked at $23M in Q4 2014. 135 funds tracked by Wall St. Rank hold CLVS as of Q1 2016.

Russell Frank Company reported no remaining Clovis Oncology, Inc. position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 2,498 Clovis Oncology, Inc. shares in Q1 2016, an estimated $86K.
Russell Frank Company first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 10 quarters.
Russell Frank Company's Clovis Oncology, Inc. position peaked at $23M in Q4 2014.
135 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.